Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/3644
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | JANSSENS, Jaak | - |
dc.contributor.author | CHIN, Y | - |
dc.contributor.author | DELEU, M | - |
dc.contributor.author | BONTE, J | - |
dc.contributor.author | STAELENS, Y | - |
dc.date.accessioned | 2007-11-29T09:57:33Z | - |
dc.date.available | 2007-11-29T09:57:33Z | - |
dc.date.issued | 1993 | - |
dc.identifier.citation | ANTICANCER RESEARCH, 13(6B). p. 2477-2483 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | http://hdl.handle.net/1942/3644 | - |
dc.description.abstract | The choice of chemotherapy for advanced breast cancer patients is based on both response rates and anticipated side effects. Two polychemotherapy regimens, ACV and NCV, were compared in an open study with 90 patients of whom 69 were evaluable both for efficacy and toxicity. Both ACV and NCV are active in metastatic breast cancer. ACV lends to more remissions in a relatively short time. NCV treatment results in a larger proportion of stable diseases. ACV causes more important alopecia, nausea and vomiting. NCV gives more anemia. The characteristics of both treatment results give the oncologist the opportunity to choose in particular clinical situations. | - |
dc.language.iso | en | - |
dc.publisher | INT INST ANTICANCER RESEARCH | - |
dc.subject.other | ADVANCED BREAST CANCER; ADRIAMYCIN; MITOXANTRONE; COMBINATION CHEMOTHERAPY | - |
dc.title | Adriamycin, cyclophosphamide and vindesine (ACV) versus mitoxantrone, cyclophosphamide and vindesine (NCV) in advanced breast-cancer | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 2483 | - |
dc.identifier.issue | 6B | - |
dc.identifier.spage | 2477 | - |
dc.identifier.volume | 13 | - |
local.format.pages | 7 | - |
dc.description.notes | LIMBURGS ONCOL CTR,HASSELT GENK,BELGIUM. CATHOLIC UNIV LEUVEN,DEPT GYNECOL ONCOL,B-3000 LOUVAIN,BELGIUM. DIENST ONCOL H HARTZIEKENHUIS,TIENEN,BELGIUM.JANSSENS, JP, LIMBURGS UNIV CENTRUM,DR L WILLEMS INST,UNIV CAMPUS GEBOUW C,B-3590 DIEPENBEEK,BELGIUM. | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.isi | A1993NE37200023 | - |
item.contributor | JANSSENS, Jaak | - |
item.contributor | CHIN, Y | - |
item.contributor | DELEU, M | - |
item.contributor | BONTE, J | - |
item.contributor | STAELENS, Y | - |
item.accessRights | Closed Access | - |
item.fulltext | No Fulltext | - |
item.fullcitation | JANSSENS, Jaak; CHIN, Y; DELEU, M; BONTE, J & STAELENS, Y (1993) Adriamycin, cyclophosphamide and vindesine (ACV) versus mitoxantrone, cyclophosphamide and vindesine (NCV) in advanced breast-cancer. In: ANTICANCER RESEARCH, 13(6B). p. 2477-2483. | - |
Appears in Collections: | Research publications |
WEB OF SCIENCETM
Citations
3
checked on Jul 21, 2024
Page view(s)
28
checked on Oct 29, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.